Physician profile
Stephen R Anthony
NPI 1760434419
$14,330.72
in general payments reported to CMS, 2019-2025
55 companies · $2,784 in 2025
The $2,784 reported for 2025 was more than what 82% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,730 · 2020: $1,293 · 2021: $1,423 · 2022: $1,681 · 2023: $1,823 · 2024: $2,599 · 2025: $2,784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,900 · Education: $304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,900.34 |
| Education | $304.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,929.86 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,671.49 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,413.20 | 2019-2025 | Ofev, Jascayd |
| Genzyme Corporation | $1,376.74 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $941.85 | 2019-2025 | Dupixent |
| Jazz Pharmaceuticals INC. | $579.10 | 2019-2025 | Xywav |
| Mylan Specialty L.P. | $523.53 | 2019-2024 | Yupelri |
| Genentech USA, INC. | $521.35 | 2019-2024 | Xolair |
| Electromed, INC. | $406.07 | 2019-2025 | Smartvest |
| United Therapeutics Corporation | $401.71 | 2021-2025 | Tyvaso, Tyvaso |
| Philips North America LLC | $379.15 | 2019-2025 | (Di7) Home Pi Undivided, Vest Therapy Und |
| Actelion Pharmaceuticals US, INC. | $331.68 | 2019-2025 | Opsumit, Uptravi |
| Novartis Pharmaceuticals Corporation | $321.75 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $316.83 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $286.72 | 2019-2022 |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $275.52 | 2021-2025 | Winrevair, Zerbaxa, Recarbrio |
| Insmed, INC. | $263.92 | 2019-2025 | Arikayce |
| Inspire Medical Systems, INC. | $164.67 | 2023-2025 | Inspire |
| Mallinckrodt Hospital Products INC. | $149.59 | 2020-2023 | Acthar |
| Axsome Therapeutics, INC. | $145.66 | 2024-2025 | Sunosi |
| Zoll Respicardia, INC. | $143.24 | 2023-2025 | Remede System |
| Sanofi-Aventis U.S. LLC | $137.47 | 2022-2023 | |
| Harmony Biosciences LLC | $128.91 | 2020-2024 | Wakix |
| Amgen INC. | $123.02 | 2022-2025 | Tezspire |
| Advanced Respiratory, INC | $122.40 | 2020-2021 | |
| Avadel Cns Pharmaceuticals, LLC | $120.69 | 2023-2025 | Lumryz |
| Baxter Healthcare | $116.89 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Abbvie INC. | $115.94 | 2022-2023 | Avycaz |
| Viatris Specialty LLC | $103.06 | 2025 | Yupelri |
| Ucb, INC. | $69.83 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.55 | 2022-2025 | Glassia |
| Verona Pharma, INC. | $64.60 | 2025 | Ohtuvayre |
| Teva Pharmaceuticals USA, INC. | $62.68 | 2020-2021 | |
| Pulmonx Corporation | $39.90 | 2019-2024 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Gilead Sciences, INC. | $37.61 | 2019-2023 | Veklury |
| Covis Pharma Gmbh | $36.33 | 2022 | |
| Circassia INC. | $35.07 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $33.72 | 2021 | |
| Phadia US INC. | $31.66 | 2020-2021 | |
| Ani Pharmaceuticals, INC. | $30.15 | 2025 | Purified Cortrophin Gel |
| Exelixis INC. | $29.76 | 2022 | |
| Inogen, INC. | $28.49 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Daiichi Sankyo INC. | $27.82 | 2024 | Enhertu |
| Eisai INC. | $26.52 | 2021 | |
| Mallinckrodt Enterprises LLC | $25.11 | 2019 | |
| Grifols USA, LLC | $24.83 | 2024 | Prolastin-C Liquid |
| Csl Behring | $24.25 | 2022 | |
| Astellas Pharma US INC | $23.69 | 2024 | Cresemba |
| Pfizer INC. | $20.46 | 2025 | |
| Abiomed | $18.60 | 2025 | |
| Shire North American Group INC | $18.05 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.84 | 2021 | |
| Lilly USA, LLC | $14.66 | 2025 | Zepbound |
| Allergan, INC. | $12.53 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Anthony listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.